Direkt zum Inhalt
Merck

A7655

Sigma-Aldrich

Atenolol

≥98% (TLC), powder, β₁-adrenoceptor antagonist

Synonym(e):

(±)-4-[2-Hydroxy-3-[(1-methylethyl)-amino]-propoxy]-benzolacetamid, 4-[2′-Hydroxy-3′-(isopropylamino)-propoxy]-phenylacetamid

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Empirische Formel (Hill-System):
C14H22N2O3
CAS-Nummer:
Molekulargewicht:
266.34
EG-Nummer:
MDL-Nummer:
UNSPSC-Code:
12352200
PubChem Substanz-ID:
NACRES:
NA.77

product name

Atenolol, ≥98% (TLC), powder

Assay

≥98% (TLC)

Form

powder

Farbe

white to off-white

Löslichkeit

H2O: 0.3 mg/mL
DMSO: 18 mg/mL
ethanol: 3.4 mg/mL

Ersteller

AstraZeneca

SMILES String

CC(C)NCC(O)COc1ccc(CC(N)=O)cc1

InChI

1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)

InChIKey

METKIMKYRPQLGS-UHFFFAOYSA-N

Angaben zum Gen

human ... ADRB1(153)
rat ... Adrb1(24925)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Anwendung

Atenolol is a β-adrenergic blocker and used in the management of hypertension. Atenolol has antianginal and antiarrhythmic properties.

Biochem./physiol. Wirkung

Selective β1-adrenoceptor antagonist; antihypertensive; antianginal; antiarrhythmic.

Leistungsmerkmale und Vorteile

This compound is featured on the β-Adrenoceptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sonstige Hinweise

Shelf-life of the solid is at least three years.

Anwendung

Produkt-Nr.
Beschreibung
Preisangaben

Standard

Produkt-Nr.
Beschreibung
Preisangaben

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 2

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Persönliche Schutzausrüstung

Eyeshields, Gloves, type N95 (US)


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Ganesha Rai et al.
Journal of medicinal chemistry, 52(20), 6474-6483 (2009-09-19)
Schistosomiasis is a chronic parasitic disease affecting hundreds of millions of individuals worldwide. Current treatment depends on a single agent, praziquantel, raising concerns of emergence of resistant parasites. Here, we continue our explorations of an oxadiazole-2-oxide class of compounds we
Hsin-Hui Chiu et al.
Mayo Clinic proceedings, 88(3), 271-276 (2013-01-17)
To assess the tolerability and efficacy of the investigational use of the angiotensin II receptor blocker losartan added to β-blockade (BB) to prevent progressive aortic root dilation in patients with Marfan syndrome (MFS). Between May 1, 2007, and September 31
Ronald V Lacro et al.
American heart journal, 165(5), 828-835 (2013-04-30)
The Pediatric Heart Network designed a clinical trial to compare aortic root growth and other short-term cardiovascular outcomes in children and young adults with Marfan syndrome randomized to receive atenolol or losartan. We report here the characteristics of the screened
Sripal Bangalore et al.
The American journal of medicine, 127(10), 939-953 (2014-06-15)
Debate exists about the efficacy of β-blockers in myocardial infarction and their required duration of usage in contemporary practice. We conducted a MEDLINE/EMBASE/CENTRAL search for randomized trials evaluating β-blockers in myocardial infarction enrolling at least 100 patients. The primary outcome
Ronald V Lacro et al.
The New England journal of medicine, 371(22), 2061-2071 (2014-11-19)
Aortic-root dissection is the leading cause of death in Marfan's syndrome. Studies suggest that with regard to slowing aortic-root enlargement, losartan may be more effective than beta-blockers, the current standard therapy in most centers. We conducted a randomized trial comparing

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.